Gert Huppertz-Hauss

10PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityImmunogenetics (incl. genetic immunology)AutoimmunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 06, 2026
Anti-TNF withdrawal or long-term treatment in ulcerative colitis (BIOSTOP): a multicentre open label, randomized controlled trial.

|Apr 12, 2026
Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study.

Maria G Maseng, Simen H Hansen, Olle Grännö

|Mar 13, 2026
Anxiety and depression in newly diagnosed patients with inflammatory bowel disease (the IBSEN III study) compared with the general population in Norway.

Ingunn Johansen, Milada C Hagen, Stine T Løkkeberg

|Apr 26, 2025
Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort.

Simen Hyll Hansen, Maria Gjerstad Maseng, Olle Grännö

|Apr 19, 2025
Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.

Eleftheria Pertsinidou, Benita Salomon, Daniel Bergemalm

|Mar 10, 2025
Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort).

Bjorn Christian Olsen, Randi Opheim, Vendel A Kristensen

Pageof 2

Frequent Collaborators

8 joint publications

Randi Opheim

8 joint publications

Marte Lie Høivik

7 joint publications

Vendel Kristensen

6 joint publications

May-Bente Bengtson